fluindione has been researched along with edoxaban in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, R; Baber, U; Boersma, E; Capranzano, P; Chen, C; Dangas, GD; Duggal, A; Hambrecht, R; Hayashida, K; Hengstenberg, C; Jin, J; Kim, HS; Laeis, P; Lang, I; Lanz, H; López-Otero, D; Mehran, R; Meincke, F; Möllmann, H; Moreno, R; Nombela-Franco, L; Nordbeck, P; Ohlmann, P; Pilgrim, T; Rodés-Cabau, J; Saito, S; Shawl, F; Thiele, H; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P; Watanabe, Y; Yamamoto, M; Zamorano, JL | 1 |
1 trial(s) available for fluindione and edoxaban
| Article | Year |
|---|---|
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Topics: 4-Hydroxycoumarins; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Mortality; Phenindione; Postoperative Complications; Pyridines; Thiazoles; Thromboembolism; Transcatheter Aortic Valve Replacement; Vitamin K | 2021 |